Dr. Woyach on the Results of the ELEVATE-TN Trial in CLL

Video

In Partnership With:

Jennifer Woyach, MD, discusses the results of the ELEVATE-TN trial in patients with treatment-naïve chronic lymphocytic leukemia.

Jennifer Woyach, MD, associate professor, The Ohio State University Comprehensive Cancer Center—James, discusses the results of the ELEVATE-TN trial in patients with treatment-naïve chronic lymphocytic leukemia (CLL).

The ELEVATE-TN study examined chlorambucil/obinutuzumab (Gazyva) versus acalabrutinib (Calquence) alone versus acalabrutinib plus obinutuzumab—a trial that led to the FDA approval of acalabrutinib, explains Woyach. Acalabrutinib alone and acalabrutinib/obinutuzumab had significantly improved progression-free survival (PFS) along with a 2-year PFS rate of about 90%, according to Woyach.

There appears to be a beneficial trend with the addition of obinutuzumab to acalabrutinib, which was predicted in preclinical studies. Additionally, obinutuzumab is a superior antibody compared with rituximab (Rituxan), says Woyach. The data need to mature before it is known which patient populations with CLL benefit from the addition of obinutuzumab, concludes Woyach.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD